Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2008, MELAS syndrome, diabetes and thyroid disease: the role of mitochondrial oxidative stress., Clin Endocrinol (oxf)
Hope DCD, Tan TMM, Bloom SR, 2018, No guts, no loss: Toward the ideal treatment for obesity in the twenty-first century, Frontiers in Endocrinology, Vol:9
et al., 2018, The effects of kisspeptin on β-cell function, serum metabolites and appetite in humans., Diabetes Obes Metab
McGlone ER, Tan TM, 2018, Of Mice Not Men? Actions of Interleukin-6 on Glucose Tolerance, Cell Metabolism, Vol:27, ISSN:1550-4131, Pages:1157-1158
et al., 2018, Surgical revision of candy cane after Roux-en-Y gastric bypass (RYGB), 9th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), WILEY, Pages:15-16, ISSN:0007-1323